#United States #Carlsbad #Active Motif #Arima Genomics #Hi-C Technology

Advancing 3D Genomics through Strategic Collaboration

In a significant move within the field of genomics, Active Motif, a premier provider of epigenetics and multiomic solutions, has established an exclusive global distribution agreement with Arima Genomics. This partnership marks a pivotal moment in enhancing research capabilities, especially in the realms of cancer diagnostics and advanced genomics.

A New Era for Genomic Research

Announced on July 6, 2026, this agreement underscores the increasing importance of understanding genomic structure and its effect on gene regulation and disease biology. Active Motif will exclusively distribute Arima's Hi-C products and services for research applications worldwide. This collaboration is designed not only to broaden Active Motif's research genomics portfolio but also to enable Arima to concentrate on its clinical diagnostics platform, Aventa.

As genomic research evolves, reliance on sequence-based analysis is shifting. The advent of 3D genome mapping technologies, such as Hi-C, has opened doors to a deeper understanding of chromatin organization, structural variations, and essential regulatory mechanisms. These advancements are crucial in addressing complex areas like cancer, neuroscience, and precision medicine, by providing insights that conventional methods may overlook.

Strengthening Research with Comprehensive Solutions

Joe Fernandez, the Chairman and Founder of Active Motif, emphasized the significance of this agreement, stating, "This partnership fortifies Active Motif’s role as a premier provider of integrated multiomic solutions. Researchers are increasingly seeking insights that combine chromatin accessibility, epigenetics, transcription factor interactions, and genome architecture." By integrating Arima's renowned Hi-C technology, Active Motif aims to enhance its service offerings, providing researchers with end-to-end solutions that tackle pressing questions in biology today.

The agreement builds on Active Motif's extensive portfolio, which includes services supporting chromatin profiling and next-generation sequencing applications. The incorporation of Hi-C technology will enable Active Motif to serve the burgeoning markets of spatial genomics and 3D biology, facilitating innovative approaches in multiomic research workflows.

Arima Genomics: A Focus on Cancer Diagnostics

On the other side of the partnership, Arima Genomics is channeling its efforts towards refining its Aventa clinical diagnostics platform, aiming to combine DNA sequence and structure in identifying cancer-driving alterations. This strategic alignment with Active Motif allows Arima to leverage their research tools to provide more effective diagnostics, increasing the likelihood of catching alterations that traditional methods might miss. Tom Willis, CEO of Arima, expressed enthusiasm about the partnership, stating, "This agreement allows us to align our research-use Hi-C technologies with Active Motif's complementary portfolio and expertise."

Implications for the Scientific Community

With the execution of this agreement, Arima's Hi-C products and services will be immediately available through Active Motif’s global distribution channels. This arrangement is expected to enhance access to innovative genomic technologies across various sectors including academia, biotechnology, and clinical research organizations.

In conclusion, this collaboration between Active Motif and Arima Genomics represents a significant advancement in genomics, providing researchers with access to cutting-edge tools and technologies. As the field continues to demand more sophisticated methods to explore the complex interactions governing gene expression and disease, partnerships like these are vital for pushing the boundaries of our understanding of biology, ultimately driving improvements in human health.

About Active Motif

Active Motif is renowned for its contributions to epigenetics and multiomics. The company equips scientists with comprehensive tools and resources to deepen their research into gene regulation, cellular function, and disease mechanisms.

About Arima Genomics

Arima Genomics leads the charge in redefining cancer diagnostics by utilizing advanced 3D genome science and Hi-C technology. It aims to uncover significant insights into cancer through its innovative Aventa clinical testing offerings.